These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 16606653)

  • 1. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis.
    Vis M; Havaardsholm EA; Haugeberg G; Uhlig T; Voskuyl AE; van de Stadt RJ; Dijkmans BA; Woolf AD; Kvien TK; Lems WF
    Ann Rheum Dis; 2006 Nov; 65(11):1495-9. PubMed ID: 16606653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.
    Güler-Yüksel M; Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Groenendael JH; Mallée C; de Bois MH; Breedveld FC; Dijkmans BA; Lems WF
    Ann Rheum Dis; 2009 Mar; 68(3):330-6. PubMed ID: 18375540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
    Maïmoun L; Couret I; Mariano-Goulart D; Dupuy AM; Micallef JP; Peruchon E; Ohanna F; Cristol JP; Rossi M; Leroux JL
    Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F; Garnero P; le Henanff A; Debiais F; Daragon A; Roux C; Sany J; Wendling D; Zarnitsky C; Ravaud P; Thomas T
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
    Fiore CE; Pennisi P; Ferro G; Ximenes B; Privitelli L; Mangiafico RA; Santoro F; Parisi N; Lombardo T
    Horm Metab Res; 2006 Jun; 38(6):417-22. PubMed ID: 16823725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
    Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Are there any positive effects of TNF-alpha blockers on bone metabolism?].
    Seriolo B; Paolino S; Sulli A; Cutolo M
    Reumatismo; 2006; 58(3):199-205. PubMed ID: 17013436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis.
    Skoumal M; Kolarz G; Haberhauer G; Woloszczuk W; Hawa G; Klingler A
    Rheumatol Int; 2005 Nov; 26(1):63-9. PubMed ID: 15889303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Fas(lpr) mice by N-3 fatty acids.
    Bhattacharya A; Rahman M; Banu J; Lawrence RA; McGuff HS; Garrett IR; Fischbach M; Fernandes G
    J Am Coll Nutr; 2005 Jun; 24(3):200-9. PubMed ID: 15930486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
    Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
    Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction.
    Geusens PP; Landewé RB; Garnero P; Chen D; Dunstan CR; Lems WF; Stinissen P; van der Heijde DM; van der Linden S; Boers M
    Arthritis Rheum; 2006 Jun; 54(6):1772-7. PubMed ID: 16736519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease.
    Hegedus D; Ferencz V; Lakatos PL; Meszaros S; Lakatos P; Horvath C; Szalay F
    J Bone Miner Res; 2002 Nov; 17(11):1961-7. PubMed ID: 12412803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.